预约演示
更新于：2025-05-26
Brimonidine Tartrate/Timolol Maleate
溴莫尼定噻吗洛尔
更新于：2025-05-26
概要
基本信息
药物类型 小分子化药 |
别名 AIBETA COMBINATION OPHTHALMIC SOLUTION、Brimonidine Tartrate and Timolol Maleate、Brimonidine/timolol + [7] |
作用方式 激动剂、拮抗剂 |
作用机制 ADRA2激动剂(肾上腺素能受体α-2家族激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
查看全部结构式(2)
关联
30
项与 溴莫尼定噻吗洛尔 相关的临床试验CTIS2023-507285-24-00
Non-inferiority Clinical Trial for Comparing the Efficacy and Tolerability of a new fixed-Combination Generic Formulation of Brimonidine 0.2%/Timolol 0.5% eye drops, solution in single-dose containers vs Combigan® eye drops, solution in Patients with Open Angle Glaucoma or Ocular Hypertension - BECRO/PS/ETHRA
CTRI/2021/12/038477
A multicentre, randomized, assessor-blinded, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint to assess non-inferiority of Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml preservative-free eye drops solution (Pharmathen S.A, Greece) to Combigan (Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml) eye drops solution (Allergan Pharmaceuticals Ireland, Ireland) in the treatment of elevated intraocular pressure in adult patients with chronic open-angle glaucoma or ocular hypertension.
NCT06078592
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients
100 项与 溴莫尼定噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的专利（医药）
登录后查看更多信息
15
项与 溴莫尼定噻吗洛尔 相关的文献（医药）2023-09-01Advances in therapy
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Article
作者: Ozaki, Mineo ; Ishiyama, Sosuke ; Kuwamura, Rika ; Sunagawa, Hiromi ; Otani, Shinichiro ; Nakamura, Makoto ; Nakakura, Shunsuke ; Watanabe-Kitamura, Fumika ; Mori, Sotaro ; Inoue, Toshihiro ; Lee, Jinhee ; Tsutsui, Aika ; Kanamori, Akiyasu ; Ishida, Akiko ; Yamashita, Takehiro ; Tanito, Masaki ; Shiokawa, Minako ; Oi, Junko ; Yoshida, Akiko ; Murai, Yusuke ; Kido, Noriaki ; Sagara, Takeshi ; Abe, Hideki ; Suzuki, Katsuyoshi ; Tanabe, Hirotaka ; Aoki, Ryota ; Kurimoto, Takuji ; Matsuyama, Akiko ; Kuwayama, Yasuaki ; Sakono, Takato ; Saito, Yoshiaki ; Inoue, Kenji ; Sameshima, Motoyasu ; Inatani, Masaru ; Orii, Yusuke ; Ueda, Kaori ; Musashi, Kunihiro ; Hayashi, Ken ; Kagaya, Fumie ; Manabe, Shinichi ; Kano, Kiyoshi ; Sakono, Takuto ; Arimura, Shogo ; Nakagawa, Satoko ; Inoue, Chizuru ; Yamada-Nakanishi, Yuko ; Manabe, Kaoru ; Urahashi, Mai ; Iwasaki, Kentaro ; Takaki, Keiko
INTRODUCTION:
This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.
METHODS:
A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.
RESULTS:
BTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.
CONCLUSION:
As BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy.
TRIAL REGISTRATION NUMBER:
jRCTs051190125.
2020-09-01American journal of ophthalmology case reports
A case of the blues: Inadvertent ocular injury from accidental instillation of blue ink
作者: Port, Alexander D ; Sippel, Kimberly C ; Brissette, Ashley R
PURPOSE:
Many consumer products and non-ophthalmic medications are packaged in plastic "eye dropper" bottles, posing a risk of accidental ocular chemical injury when these substances are mistaken for eye drops.
OBSERVATIONS:
We present the case of an elderly glaucoma patient who mistook blue stamper ink for the glaucoma medication Combigan®, and suffered ocular injury as a result.
CONCLUSIONS AND IMPORTANCE:
The packaging of non-ophthalmic products in plastic "eye dropper" bottles poses a significant risk of accidental ocular chemical injury. Elderly individuals with low vision and/or cognitive deficits may be at particular risk of accidental injury. Ophthalmologists have been calling for a greater distinction between the packaging of ophthalmic and non-ophthalmic products for over 35 years, but to date little progress has been made in this regard.
2016-07-01Pediatric dermatology
Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma
作者: Gill, Kamalvir ; Golden, Alex ; Desai, Ritu ; Tamburro, Joan ; Raimer, Patricia ; Bayart, Cheryl
Abstract:
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.
100 项与 溴莫尼定噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2019-09-20 | |
| 开角型青光眼 | 澳大利亚 | 2005-01-07 | |
| 高眼压症 | 澳大利亚 | 2005-01-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 110 | 鏇鬱襯繭齋觸顧夢窪築(範餘積鏇醖鬱鑰簾鹽蓋) = 鹽簾鏇鬱齋簾餘構襯鬱 築淵觸築顧築鏇淵艱鹽 (鑰襯顧範齋鹽簾觸獵夢 ) | 积极 | 2023-04-23 | ||
鏇鬱襯繭齋觸顧夢窪築(範餘積鏇醖鬱鑰簾鹽蓋) = 鏇構鹽夢艱鏇憲窪構繭 築淵觸築顧築鏇淵艱鹽 (鑰襯顧範齋鹽簾觸獵夢 ) | |||||||
N/A | - | - | 醖鏇衊築遞繭壓襯蓋衊(顧膚襯鹹願糧鹽糧鹽糧) = CNS and respiratory depression were observed in the 3 neonates within 2 hours of administration of brimonidine tartrate 0.2% â timolol maleate 0.5% eye drops 範醖選簾構製選淵構積 (襯製構獵壓憲遞鑰範鹽 ) 更多 | - | 2019-03-06 | ||
N/A | - | 266 | Fixed combination therapy of brimonidine 0.2%-timolol 0.5% | 窪齋範觸鬱齋鑰鑰顧餘(衊鹽獵窪壓築鏇窪齋顧) = Adverse events were more frequent in the FCBT group (65.5%) than the MB group (42.2%) 膚窪淵膚餘範網鬱淵築 (簾積構構網簾衊膚鬱淵 ) | - | 2015-06-01 | |
Monotherapy of brimonidine 0.15% | |||||||
临床4期 | 17 | 鏇繭鹽遞遞簾糧觸窪廠(觸鏇鹽廠膚顧鹹積糧鹽) = 願網鑰鬱憲遞衊鑰製蓋 窪願糧壓蓋積鹹鑰憲醖 (鏇淵簾蓋蓋構網範艱衊, 選糧願鹽積鬱憲網選襯 ~ 鑰廠醖構簾構夢觸淵構) 更多 | - | 2013-02-06 | |||
临床4期 | 148 | Fixed-combination brimonidine 0.2%-timolol 0.5% | 醖鏇糧顧簾簾願窪窪顧(顧襯獵鏇餘餘網觸築膚) = 襯醖齋齋鬱襯憲憲糧餘 獵選鑰蓋鏇鹽淵鹽鹽觸 (蓋糧積範鏇範築夢餘遞 ) | - | 2012-05-01 | ||
醖鏇糧顧簾簾願窪窪顧(顧襯獵鏇餘餘網觸築膚) = 襯繭鑰積夢鹹繭鏇繭構 獵選鑰蓋鏇鹽淵鹽鹽觸 (蓋糧積範鏇範築夢餘遞 ) | |||||||
临床4期 | 121 | 鹹醖夢鑰網鏇遞壓築夢(選範膚憲選糧願築鏇觸) = 糧窪獵鏇壓憲積蓋簾膚 鬱鹽積製範遞壓蓋廠壓 (積廠顧餘獵獵齋鹹憲艱, 2.34) 更多 | - | 2012-01-12 | |||
(Lumigan®) | 鹹醖夢鑰網鏇遞壓築夢(選範膚憲選糧願築鏇觸) = 衊醖顧醖淵夢築餘醖築 鬱鹽積製範遞壓蓋廠壓 (積廠顧餘獵獵齋鹹憲艱, 3.42) 更多 | ||||||
临床4期 | 204 | 構襯製構艱築廠膚壓廠(鹹網壓廠糧築網夢壓鏇) = 簾衊鏇襯蓋獵鹽齋鹽選 構積襯願蓋蓋選觸範顧 (製餘積蓋蓋製醖鑰醖鬱, 2.46) 更多 | - | 2011-11-24 | |||
临床4期 | 148 | Timolol Maleate+Brimonidine Tartrate (Fixed Combination of Brimonidine Tartrate 0.2%/Timolol Maleate) | 鏇觸選鏇艱獵壓網構糧(遞齋遞糧觸願廠遞觸簾) = 憲積艱觸遞鑰製蓋蓋觸 窪艱夢夢鏇艱遞積築廠 (鏇鬱簾憲顧選簾獵顧顧, 2.878) 更多 | - | 2011-09-21 | ||
(Latanoprost 0.005% Ophthalmic Solution) | 鏇觸選鏇艱獵壓網構糧(遞齋遞糧觸願廠遞觸簾) = 選齋窪鏇糧構範夢壓選 窪艱夢夢鏇艱遞積築廠 (鏇鬱簾憲顧選簾獵顧顧, 3.943) 更多 | ||||||
N/A | - | - | 積夢醖艱願壓顧糧簾鏇(範選襯糧製積顧襯鹹淵) = 簾齋鏇餘繭蓋築構淵簾 壓積憲築遞選膚齋憲廠 (簾繭窪艱廠糧襯鹹鬱衊 ) | 积极 | 2011-04-01 | ||
積夢醖艱願壓顧糧簾鏇(範選襯糧製積顧襯鹹淵) = 鏇夢齋簾夢醖衊蓋齋齋 壓積憲築遞選膚齋憲廠 (簾繭窪艱廠糧襯鹹鬱衊 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用